Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study

Edwin M. Posadas*, Rafi S. Ahmed, Theodore Karrison, Russell Z. Szmulewitz, Peter H. O'Donnell, James L. Wade, James Shen, Murali Gururajan, Margarit Sievert, Walter M. Stadler

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study'. Together they form a unique fingerprint.

Medicine & Life Sciences